
NIH Launches Public-Private Cancer Vaccine Initiative to Accelerate Personalized Treatments
The National Institutes of Health (NIH) is launching a public-private partnership in December to accelerate the development of personalized cancer vaccines. This initiative, modeled after the rapid success of COVID-19 vaccines, aims to reduce the timeline for bringing new treatments to market from 8-15 years to 7-10 years. The program will initially focus on pancreatic, liver, and colorectal cancers, as well as pediatric tumors. The announcement triggered a significant rally in vaccine-related stocks, with Novavax and Moderna leading gains, driven by the promise of faster clinical trials and reduced R&D costs for participating companies.








